Family Lifestyle Actions and Risk Education Study (FLARE)

April 16, 2019 updated by: Yelena Wu, University of Utah

FLARE: Family Lifestyle Actions and Risk Education Study for Children With a Familial Risk for Melanoma

The overall purpose of this study is to test the feasibility, acceptability, and preliminary efficacy of a family-focused behavioral intervention ("FLARE", which stands for Family Lifestyle Actions and Risk Education) that aims to improve adherence to melanoma preventive behaviors among children at elevated risk for the disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Test the feasibility and acceptability of FLARE, a family-focused behavioral intervention that is designed to improve and maintain adherence to photoprotection (e.g., use of sunscreen) and screening (e.g., implementation of self skin exams). We expect that the feasibility of the intervention will be supported by at least 75% of participants attending at least 3 intervention sessions. We also expect that the acceptability of the intervention (e.g., overall satisfaction, ease of participation, perceived utility of intervention) will be supported by mean ratings that indicate adequate levels of acceptability across participants (e.g., mean rating of "satisfied" or "very satisfied" for overall satisfaction).

Pilot test the efficacy of the FLARE intervention with children at elevated risk for melanoma and their primary caregiver.

We will also explore the potential impact of the FLARE intervention on melanoma preventive behaviors among siblings of the child who receives the intervention, as well as the child's other parent/caregiver (if another parent/caregiver is available).

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Huntsman Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 110 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Children

  • Are 8-17 years old AND
  • Are at risk for melanoma due to having a first degree relative with a history of melanoma and/or at least 3 second or third degree relatives on the same side of the family with a history of melanoma AND/OR
  • Have personally received genetic testing for the CDKN2A/p16 genetic mutation and/or has one or more family members who received CDKN2A/p16 testing

Adults

  • Are at least 18 years old AND
  • Are the primary caregiver for the child participating in the study (defined as the individual who is responsible for daily implementation of health-related tasks for the child) AND
  • Have at least one child under age 18 who is living in the same household AND
  • Have a personal history of melanoma and/or family history of melanoma) AND/OR
  • Have personally received genetic testing for the CDKN2A/p16 genetic mutation and/or has one or more family members who received CDKN2A/p16 testing

Exclusion Criteria:

  • Individuals who do not speak, read/write English will be excluded because FLARE involves regular interaction between study staff and research participants in English and completion of study questionnaires and interviews in English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FLARE intervention
All FLARE participants enrolled will receive the intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent of Participants Retained Throughout Intervention as Assessed by Session Attendance Recorded by Interventionist
Time Frame: Week 9 (post-intervention)
Session attendance will be recorded by the interventionist at each scheduled session. The percent of participants who are retained throughout the 3 session intervention will be calculated.
Week 9 (post-intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Photoprotective Behaviors Assessed With the Sun Habits Survey
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
"These next questions ask about what you have done in the past month if you were outdoors in the sun for 15 minutes or more. How often did you..." Minimum value = 1; Maximum value = 5; Higher scores indicate a better outcome
Weeks 1 (baseline), 3,5,7,9,13
Photoprotective Behaviors Assessed With the PALE Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
Protection-Adjusted Length of Exposure Index (PALE) Assesses photoprotective behavior during reported activities to yield daily minutes of unprotected sun exposure during each time frame
Weeks 1 (baseline), 3,5,7,9,13
Skin Self-exam Occurrence Assessed Via Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
Number of participants who received a skin self-exam during each time frame
Weeks 1 (baseline), 3,5,7,9,13
Skin Self-exam Occurrence Assessed Via Diary
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
Number of participants who received a skin self-exam during each time frame interval
Weeks 1 (baseline), 3,5,7,9,13
Sunburn Occurrence Assessed Via Diary
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
Number of participants who got a sunburn during each time frame interval
Weeks 1 (baseline), 3,5,7,9,13
Sunburn Occurrence Assessed Via Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
Number of participants who received a sunburn during each time frame.
Weeks 1 (baseline), 3,5,7,9,13
Ultraviolet Radiation (UVR) Exposure Assessed Via Dosimeter Device
Time Frame: Weeks 1 (baseline),9,13
Change of weekly average UV intake from Week 1 (baseline) to Week 9 (post-intervention) and from Week 9 to Week 13 (1-month follow up)
Weeks 1 (baseline),9,13
Ultraviolet Radiation (UVR) Exposure Assessed Via PALE Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
Protection-Adjusted Length of Exposure Index (PALE) Assesses UVR exposure during reported activities to yield daily minutes of unprotected sun exposure during each time frame
Weeks 1 (baseline), 3,5,7,9,13
Degree of Tan on Skin Assessed Via Reflectance Spectroscopy
Time Frame: Weeks 1 (baseline),9,13
Mean degree of tan on skin assessed via reflectance spectroscopy of 4 different body parts (exposed wrist, outer arm, chin, and face) at each time frame. Measurements were taken using a spectrophotometer to quantify skin color. Melanin index values were recorded, with a higher value representing more melanin in the skin (i.e., darker skin).
Weeks 1 (baseline),9,13
Photoprotection Behavior Changes Assessed Via Questionnaire
Time Frame: Weeks 1,9,13

Mean difference for each photoprotection behavior from Week 1 (pre-intervention) to Week 9 (post-intervention) and from Week 9 to Week 13 (1 month follow-up).

"These next questions ask about what you have done in the past month if you were outdoors in the sun for 15 minutes or more. How often did you..." Minimum value = 1; Maximum value = 5; A higher mean difference indicates a better outcome

Weeks 1,9,13
Skin Self-exam Behavior Changes
Time Frame: Weeks 1,9,13

Mean difference for frequency of skin self-exam and thoroughness of skin self-exam (measured by number of body parts examined) from Week 1 (pre-intervention) to Week 9 (post-intervention) and from Week 9 to Week 13 (1 month follow-up). (SSE = skin self-exam)

Change in frequency of SSE: "In the past month, how often did you check your skin for any new or changed moles or growths?" 1 = SSE less than once a month, 2 = SSE once a month, 3 = SSE more than once a month; higher mean difference indicates a better outcome.

Change in thoroughness of SSE: "In the past month, which of the body parts listed below were checked for any new or changed moles or growths" Minimum value = 0 (checked 0 body parts during SSE); Maximum value = 15 (checked 15 body parts during SSE); higher mean difference indicates a better outcome

Weeks 1,9,13
Acceptability of Intervention Assessed Via Questionnaire
Time Frame: Week 9

"In these next 15 questions, we want to learn more about your thoughts about what you learned through the FLARE sessions you've had with us in-person and via WebEx or phone. Please indicate how much you agree with each statement." 15 total constructs summed, each was on the same 5 point Likert scale (1 = Strongly Disagree, 5 = Strongly Agree).

Minimum value = 1; Maximum Value = 75; higher score means a better outcome (better acceptability)

Week 9

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2016

Primary Completion (Actual)

November 1, 2017

Study Completion (Actual)

November 1, 2017

Study Registration Dates

First Submitted

July 17, 2016

First Submitted That Met QC Criteria

July 22, 2016

First Posted (Estimate)

July 27, 2016

Study Record Updates

Last Update Posted (Actual)

May 8, 2019

Last Update Submitted That Met QC Criteria

April 16, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe